Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Guardant Health Inc (GH) - Product Pipeline Analysis, 2020 Update

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

TABLE OF CONTENTS

Guardant Health Inc Company Overview
Guardant Health Inc Company Snapshot
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc Pipeline Analysis Overview
Guardant Health Inc - Key Facts
Guardant Health Inc - Major Products and Services
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Pipeline Products Overview
Anti-RSP03 Antibody Based Blood Test
Anti-RSP03 Antibody Based Blood Test Product Overview
cfDNA Diagnostic Assay
cfDNA Diagnostic Assay Product Overview
Gene-Based Test - Lung Cancer
Gene-Based Test - Lung Cancer Product Overview
Gene-Based Test - Lung Cancer Clinical Trial
GUARDANT360
GUARDANT360 Product Overview
GUARDANT360 Clinical Trial
Guardant360 CDx Test - Tagrisso
Guardant360 CDx Test - Tagrisso Product Overview
Guardant360 CDx Test - Tepotinib
Guardant360 CDx Test - Tepotinib Product Overview
Guardant360 Companion Diagnostic Assay - Glesatinib
Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
GuardantOMNI Test - Imfinzi
GuardantOMNI Test - Imfinzi Product Overview
GuardantOMNI Test - Imfinzi Clinical Trial
LUNAR-2 Assay
LUNAR-2 Assay Product Overview
LUNAR-2 Assay Clinical Trial
Guardant Health Inc - Key Competitors
Guardant Health Inc - Key Employees
Guardant Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Guardant Health Inc, Recent Developments
Feb 24, 2020: Guardant Health reports fourth quarter and full year 2019 financial results and provides full year 2020 outlook
Jan 21, 2020: Guardant Health appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
Jan 13, 2020: Guardant Health, NRG Oncology begin NRG-GI005 COBRA trial
Jan 12, 2020: Guardant Health and NRG Oncology initiate randomized trial to investigate circulating tumor DNA guided adjuvant therapy in stage II colon cancer
Dec 19, 2019: Guardant Health receives expanded medicare coverage for Guardant360 across the vast majority of solid tumor cancers
Dec 13, 2019: Large-scale study shows Guardant360 effectively guides precision oncology treatment in metastatic breast cancer patients
Dec 12, 2019: Blood test can quickly match advanced breast cancer patients to targeted treatments
Dec 11, 2019: Study shows only 40 percent of patients with metastatic colon cancer receive guideline-recommended biomarker testing
Nov 07, 2019: Guardant health reports third quarter 2019 financial results and raises 2019 revenue guidance
Oct 24, 2019: Guardant Health initiates trial for CRC blood test
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Indication
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc, Key Facts
Guardant Health Inc, Major Products and Services
Guardant Health Inc Number of Pipeline Products by Development Stage
Guardant Health Inc Pipeline Products Summary by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Ongoing Clinical Trials Summary
Anti-RSP03 Antibody Based Blood Test - Product Status
Anti-RSP03 Antibody Based Blood Test - Product Description
cfDNA Diagnostic Assay - Product Status
cfDNA Diagnostic Assay - Product Description
Gene-Based Test - Lung Cancer - Product Status
Gene-Based Test - Lung Cancer - Product Description
Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
GUARDANT360 - Product Status
GUARDANT360 - Product Description
GUARDANT360 - A Multiple Parallel Cohort, Multi-centre Phase IIa Trial Aiming to Provide Proof of Principle Efficacy for Designated Targeted Therapies in Patients with Advanced Breast Cancer Where the Targetable Mutation is Identified Through ctDNA
GUARDANT360 - A Phase 1b/II, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies
GUARDANT360 - A Prospective Observational Study on the Efficacy of Multiplex Genetic Analysis by Means of a Next-generation Sequencer Using Cell-free DNA
GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection
GUARDANT360 - Multicenter Phase II Study to Evaluate Efficacy and Safety of Combination Therapy with Trastuzumab and Pertuzumab in Patients with HER2-positive Metastatic Colorectal Cancer
GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
GUARDANT360 - Noninvasive Versus Invasive Lung Evaluation
GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial
GUARDANT360 - Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer
Guardant360 CDx Test - Tagrisso - Product Status
Guardant360 CDx Test - Tagrisso - Product Description
Guardant360 CDx Test - Tepotinib - Product Status
Guardant360 CDx Test - Tepotinib - Product Description
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
GuardantOMNI Test - Imfinzi - Product Status
GuardantOMNI Test - Imfinzi - Product Description
GuardantOMNI Test - Imfinzi - A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care Versus Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
GuardantOMNI Test - Imfinzi - A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-cell Lung Cancer (NSCLC) (MYSTIC)
LUNAR-2 Assay - Product Status
LUNAR-2 Assay - Product Description
LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Guardant Health Inc, Key Employees
Guardant Health Inc, Subsidiaries
Glossary

List Of Figures

Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Guardant Health Inc (GH) - Product Pipeline Analysis, 2020 Update

Guardant Health Inc (GH) - Product Pipeline Analysis, 2019 Update

Binx Health Inc - Product Pipeline Analysis, 2021 Update

Aspira Womens Health Inc (AWH) - Financial and Strategic SWOT Analysis Review

FAQs